Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$1.48 -1.7%	$1.35	$0.87 ▼ $6.78	$147.49M	0.74	835,675 shs	233,289 shs
ALVR AlloVir	$2.50 -2.3%	$3.45	$7.96 ▼ $24.15	$12.61M	0.63	15,256 shs	35,701 shs
IMVT Immunovant	$16.80 0.0%	$15.33	$12.72 ▼ $34.47	$2.87B	0.63	1.22 million shs	511,903 shs
REPL Replimune Group	$9.45 -1.0%	$9.05	$6.44 ▼ $17.00	$728.50M	0.61	863,982 shs	581,094 shs
RGNX REGENXBIO	$8.73 +1.3%	$8.99	$5.04 ▼ $15.36	$437.90M	1.06	930,242 shs	423,944 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	0.00%	-0.34%	-1.01%	+46.04%	-66.40%
ALVR AlloVir	0.00%	-4.58%	-19.61%	-64.69%	-84.47%
IMVT Immunovant	0.00%	+4.37%	+0.20%	+16.78%	-37.50%
REPL Replimune Group	0.00%	+1.29%	-8.96%	+26.17%	+16.52%
RGNX REGENXBIO	0.00%	+4.05%	-9.16%	+47.22%	-19.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALEC Alector	3.7437 of 5 stars	3.1	3.0	0.0	4.5	0.6	2.5	0.0
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	1.4067 of 5 stars	3.5	2.0	0.0	0.0	0.0	1.7	0.0
REPL Replimune Group	4.1817 of 5 stars	3.6	1.0	0.0	4.5	2.4	2.5	0.6
RGNX REGENXBIO	4.5239 of 5 stars	3.4	3.0	0.0	4.6	2.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.14	Hold	$4.00	171.19% Upside
ALVR AlloVir	0.00	N/A	N/A	N/A
IMVT Immunovant	2.90	Moderate Buy	$38.33	128.12% Upside
REPL Replimune Group	3.13	Buy	$20.83	120.46% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	262.26% Upside

Current Analyst Ratings Breakdown

Latest ALEC, ALVR, RGNX, IMVT, and REPL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/20/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
6/9/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
6/2/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $22.00
5/9/2025	ALEC Alector	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
4/22/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$38.00 ➝ $17.00
4/17/2025	RGNX REGENXBIO	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $12.00

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$100.56M	1.47	N/A	N/A	$1.29 per share	1.14
ALVR AlloVir	N/A	N/A	N/A	N/A	$29.35 per share	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	$5.40 per share	N/A
RGNX REGENXBIO	$83.33M	5.25	N/A	N/A	$5.24 per share	1.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$119.05M	-$1.26	N/A	N/A	N/A	-139.74%	-100.58%	-25.15%	8/6/2025 (Estimated)
ALVR AlloVir	-$190.42M	-$20.23	N/A	∞	N/A	N/A	-71.03%	-61.27%	8/7/2025 (Estimated)
IMVT Immunovant	-$413.84M	-$2.74	N/A	N/A	N/A	N/A	-80.60%	-71.89%	8/5/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.07	N/A	N/A	N/A	N/A	-57.98%	-45.21%	8/14/2025 (Estimated)
RGNX REGENXBIO	-$227.10M	-$3.11	N/A	N/A	N/A	-100.62%	-53.29%	-30.84%	8/7/2025 (Estimated)

Latest ALEC, ALVR, RGNX, IMVT, and REPL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.10	3.34	3.34
ALVR AlloVir	N/A	86.78	86.78
IMVT Immunovant	N/A	11.16	11.16
REPL Replimune Group	0.17	7.95	7.95
RGNX REGENXBIO	N/A	2.93	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
ALVR AlloVir	66.05%
IMVT Immunovant	47.08%
REPL Replimune Group	92.53%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
ALEC Alector	9.10%
ALVR AlloVir	32.07%
IMVT Immunovant	5.90%
REPL Replimune Group	8.80%
RGNX REGENXBIO	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	99.99 million	90.89 million	Optionable
ALVR AlloVir	110	5.04 million	3.43 million	Optionable
IMVT Immunovant	120	170.92 million	160.84 million	Optionable
REPL Replimune Group	210	77.09 million	70.30 million	Optionable
RGNX REGENXBIO	370	50.16 million	43.75 million	Optionable

ALEC, ALVR, RGNX, IMVT, and REPL Headlines

Recent News About These Companies

RGNX | REGENXBIO Inc. Annual Income Statement - MarketWatch

July 6 at 2:10 AM | marketwatch.com

Janney Montgomery Scott LLC Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX)

July 4 at 3:11 AM | marketbeat.com

REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

June 30, 2025 | marketbeat.com

Assenagon Asset Management S.A. Sells 283,399 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

June 16, 2025 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Stock Price Up 6.1% - What's Next?

June 11, 2025 | marketbeat.com

A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts

June 9, 2025 | benzinga.com

REGENXBIO's (RGNX) Buy Rating Reaffirmed at Chardan Capital

June 9, 2025 | marketbeat.com

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

June 6, 2025 | seekingalpha.com

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update

June 6, 2025 | biopharmadive.comB

RegeNXBio shares fall, despite positive new data on RGX-202

June 6, 2025 | thepharmaletter.comT

Regenxbio’s Duchenne gene therapy data positive as shares falter

June 5, 2025 | bioworld.comB

Regenxbio Fails To Best Sarepta’s Elevidys With New Data for DMD Gene Therapy

June 5, 2025 | biospace.comB

REGENXBIO updates Phase 1/2 data for Duchenne candidate

June 5, 2025 | msn.com

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

June 5, 2025 | benzinga.com

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

June 5, 2025 | prnewswire.com

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

June 2, 2025 | prnewswire.com

Regenxbio at RBC Conference: Strategic Moves and Clinical Progress

May 22, 2025 | investing.com

REGENXBIO Inc.: REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 20, 2025 | finanznachrichten.de

REGENXBIO announces royalty monetization agreement for up to $250M

May 20, 2025 | msn.com

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 19, 2025 | prnewswire.com

REGENXBIO Inc. (NASDAQ:RGNX) Director Sells $162,961.82 in Stock

May 15, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, ALVR, RGNX, IMVT, and REPL Company Descriptions

Alector NASDAQ:ALEC

$1.48 -0.03 (-1.67%)

Closing price 07/3/2025 03:51 PM Eastern

Extended Trading

$1.50 +0.02 (+1.69%)

As of 04:01 AM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

AlloVir NASDAQ:ALVR

$2.50 -0.06 (-2.34%)

As of 07/3/2025

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Immunovant NASDAQ:IMVT

$16.80 -0.01 (-0.04%)

Closing price 07/3/2025 02:41 PM Eastern

Extended Trading

$16.80 +0.00 (+0.01%)

As of 04:03 AM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Replimune Group NASDAQ:REPL

$9.45 -0.10 (-1.05%)

Closing price 07/3/2025 03:03 PM Eastern

Extended Trading

$9.48 +0.03 (+0.26%)

As of 04:02 AM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

REGENXBIO NASDAQ:RGNX

$8.73 +0.11 (+1.28%)

Closing price 07/3/2025 03:52 PM Eastern

Extended Trading

$8.74 +0.00 (+0.06%)

As of 07/3/2025 04:33 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time